Core Viewpoint - WuXi Biologics (02269) announced the issuance of a total of 3.51 million shares on November 7, 2025, due to the exercise of options [1] Company Summary - The company is set to issue 3.51 million shares as a result of option exercises [1]

如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 | 是 | | | | 證券代號 (如上市) | 02269 | 說明 | | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | | 庫存股份變動 | | | | | 事件 | | 已發行股份（不包括庫存股份）數 目 | | 佔有關事件前的現有已發 行股份（不包括庫存股 份）數目百分比 (註3) | 庫存股份數目 | 每股發行/出售價 (註4) | | 已發行股份總數 | | 於下列日期開始時的結存(註1) ...

Core Viewpoint - WuXi Biologics (02269) announced the issuance of 6 million ordinary shares on November 6, 2025, as part of the stock option plan adopted prior to its initial public offering in January 2016, which was revised on August 10, 2016 [1] Summary by Category - **Company Actions** - The company will issue 6 million ordinary shares as part of the stock option plan [1] - **Timeline** - The issuance is scheduled for November 6, 2025 [1] - **Plan Details** - The stock option plan was initially adopted on January 5, 2016, and revised on August 10, 2016 [1]

智通财经APP讯，药明生物(02269)发布公告，于2025年11月6日，根据公司于2016年1月5日采纳的首次 公开发售前购股权计划(于2016年8月10日修订)为行使期权而发行600万股普通股。 ...

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： WuXi Biologics (Cayman) Inc. 藥明生物技術有限公司*（於開曼群島註冊成立的有限公司）*僅供識別 呈交日期： 2025年11月6日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) 02269 | 說明 | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | | 庫存股份變動 | | | ...

呈交日期: 2025年11月5日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02269 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 6,000,000,000 | USD | 0.000008333333 | USD | | 50,000 | | 增加 / 減少 (-) | | | 0 | | | USD | | 0 | | 本月底結存 | | | 6,000,000,000 | USD | 0.000008333333 | USD | | 50,000 | 本月底法定/註冊股本總額： USD 50,000 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年10月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司 ...

Core Insights - WuXi Biologics has been included in the 2025 Hang Seng Corporate Sustainability Benchmark Index, being the only pharmaceutical company recognized in this index [1][10] - The company has also been previously honored with inclusion in the HSI ESG Index and the Hang Seng ESG 50 Index, highlighting its strong ESG performance [1][10] Sustainability Recognition - The Hang Seng Corporate Sustainability Benchmark Index acknowledges publicly listed companies with outstanding ESG performance, based on an annual sustainability assessment by the Hong Kong Quality Assurance Agency (HKQAA) [2] - WuXi Biologics has received multiple accolades for its sustainability efforts, including MSCI AAA ESG Rating, EcoVadis Platinum Medal, and recognition in the Dow Jones Sustainability Indices [5] Commitment to Sustainability - WuXi Biologics integrates sustainability principles into its business model, focusing on energy and resource efficiency, governance transparency, and employee welfare [3][8] - The company is aligned with the United Nations Sustainable Development Goals and has set greenhouse gas emissions-reduction targets approved by the Science Based Targets initiative (SBTi) [4] Business Operations - WuXi Biologics operates as a global provider of biologics Green CRDMO solutions, supporting 864 integrated client projects, including 24 in commercial manufacturing as of June 30, 2025 [7] - The company employs over 12,000 skilled professionals across various countries, leveraging technology and expertise to deliver efficient and cost-effective solutions [6][7]

Group 1 - WuXi Biologics (02269) announced the issuance of a total of 210,000 shares due to the exercise of options from October 2 to October 16, 2025 [1] - On October 16, 2025, the company will cancel 23.18 million shares that have been repurchased [1]

Core Points - WuXi Biologics (02269) announced the issuance of a total of 210,000 shares due to the exercise of options from October 2 to October 16, 2025 [1] - On October 16, 2025, the company will cancel 23.18 million shares that have been repurchased [1]

Core Viewpoint - WuXi Biologics (02269.HK) announced the exercise of a share issuance plan for 46,000 shares on October 16, 2025 [1] Summary by Category - Company Announcement - WuXi Biologics will issue 46,000 shares as part of its share plan on October 16, 2025 [1]